Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie

Madrigal Statement on the Passing of Dr. Stephen Harrison

GlobeNewswire Inc.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

2 Under-the-Radar Growth Stocks to Consider

The Motley Fool

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics

The Motley Fool

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

1 No-Brainer Growth Stock to Buy Now

The Motley Fool

Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals

Zacks Investment Research

Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals

The Motley Fool

Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?

The Motley Fool

2 Top Biotech Buyout Candidates

Zacks Investment Research

Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock

The Motley Fool

This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?

The Motley Fool

Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?

The Motley Fool

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

GlobeNewswire Inc.

Madrigal Pharmaceuticals Announces Proposed Public Offering

GlobeNewswire Inc.

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

The Motley Fool

Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday

Benzinga

Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH

Zacks Investment Research

Madrigal’s stock surges as FDA approves first drug for liver disease MASH

MarketWatch

Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket

Benzinga

Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH

MarketWatch

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

GlobeNewswire Inc.

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals

Zacks Investment Research

Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.

The Motley Fool

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Rare Stock Picks In February 2024 - From 32 Discerning Analysts

Seeking Alpha

1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247?

The Motley Fool

Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

GlobeNewswire Inc.

1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street

The Motley Fool

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade)

Seeking Alpha

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Eli Lilly’s quarterly results top estimates as obesity, diabetes drugs gain insurance coverage

MarketWatch

'The cautionary signals are off the charts.' Market correction warnings appear

MarketWatch

'The cautionary signals are off the charts.' Market correction warnings appear

MarketWatch

'The cautionary signals are off the charts.' Market correction warnings appear

MarketWatch

2 Rising Biotechs That Could Become the Next Novo Nordisk

The Motley Fool

2 Stocks That Could Soar This Year: Are They Buys?

The Motley Fool

Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development

Benzinga

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

GlobeNewswire Inc.

Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc.

3 Stocks That Could Be Monster Winners in 2024

The Motley Fool

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

These 2 Stocks Could Be About to Soar: Are They Buys?

The Motley Fool

Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money

The Motley Fool

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?

Benzinga